Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mind Medicine Inc (MMED.NE)

Mind Medicine Inc (MMED.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Mind Medicine Inc One World Trade Center Suite 8500 New York NY 10007 USA

https://www.definiumtx.com P: 212-220-6633

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Key Statistics

Overview:

Market Capitalization, $K 1,050,465
Shares Outstanding, K 70,501
% of Institutional Shareholders 2.38%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -108,679 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -67,265 K

Growth:

1-Year Return 265.20%
3-Year Return -67.32%
5-Year Return 0.00%

Per-Share Information:

Most Recent Earnings -0.59 on 11/02/23
Next Earnings Date N/A
Earnings Per Share ttm -2.44
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 08/29/22

MMED.NE Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -85.59%
Return-on-Assets % -60.39%
Profit Margin % 0.00%
Debt/Equity 0.09
Price/Sales N/A
Price/Book 9.91
Book Value/Share 1.50
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar